Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Barron Von Hymen who wrote (3797)	6/30/1998 12:04:00 PM
From: Ally	Read Replies (1) \| Respond to of 9523

>> DLJ is the firm that recommended TDFX at 18 as a strong buy, subsequently it trades at 15 now and still floundering. << I checked the PTEK thread just to make sure that DLJ was the firm that recommended PTEK, and it was. On May 21st when the stock had fallen from $26 (the time the analyst appeared on CNBC and said at that price it was a "gift")to $24, the firm issued another public posting to reiterate their strong recommendation. The stock continued to plummet to $16. A week after, PTEK issued a press release about some of their large customers going chapter 11, and that earnings will also suffer cause it is having difficulties digesting their last year's acquisitions. The stock plummeted further to $7, before recovering recently to $8. A gift to investors indeed. My point? I'm happy to ignore all of their wise commentary on how they see PFE's future.